Drug intelligence / Profile preview

UIO 525

Development stage: Preclinical
Lead developer: TransCode Therapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies

Overview

UIO 525 is a genetically-engineered oncolytic adenovirus developed for cancer immunotherapy, specifically targeting muscle-invasive bladder cancer (MIBC). Originally part of a preclinical program at Unleash Immuno Oncolytics, the drug was licensed to TransCode Therapeutics in 2024 as part of a broader portfolio including UIO 524 and UIO 526. UIO 525 is designed to selectively replicate within and lyse tumor cells, a process that releases tumor-associated antigens and stimulates a systemic anti-tumor immune response. This next-generation oncolytic virus aims to provide a therapeutic option for solid tumors that may overcome the limitations of earlier viral therapies, potentially offering a less invasive alternative to radical cystectomy for bladder cancer patients.

Beyond the preview

Go deeper on UIO 525.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UIO 525.

Explore the full profile